Lung Cancer
Read Time: 2 mins

Treatment Disparities in Small Cell Lung Cancer

Copy Link
Published Online: Nov 26th 2018 Oncology & Hematology Review. 2018;14(2):70–1 DOI:
Authors: Stephen G Chun
Quick Links:
Article Information

Lung cancer accounts for the greatest proportion of cancer deaths in the US. Small cell lung cancer (SCLC) accounts for around 10–15% of all lung cancers.1 It is a highly aggressive malignancy, characterized by a high proliferation rate and early metastasis, for which the most effective first-line treatment modality is combined chemotherapy and radiation therapy.2 However, a recent National Cancer database analysis of initial management of all limited-stage SCLC cases from 2004–2013 involving 70,247 patients revealed substantial disparities in access to these therapies.3 In an expert interview, Stephen G Chun discusses the findings of this study and how these disparities can be reduced.

Q. What did the recent National Cancer Database analysis reveal about treatment disparities in small cell lung cancer?

The analysis showed that large numbers of patients with limited-stage or curable SCLC were not receiving the standard of care treatment that is concurrent chemotherapy and thoracic radiation. Roughly half of patients did not get radiation and 20% of patients got neither chemotherapy nor radiation.3,4 This is alarming because concurrent chemotherapy and radiation have been considered the standard of care for decades.

Q. What impact has limited access to standard of care therapies had on overall survival in this patient population?

For patients who received both chemotherapy and radiation, their median survival was about 18 months and for patients who received neither chemotherapy nor radiation survival was a mere 3–4 months. These survival times really speak for themselves.

Q. What are the obstacles to receiving combined radiotherapy and chemotherapy for small cell lung cancer?

It was observed that patients with government issued Medicare/Medicaid insurance were just as likely to get chemotherapy as patients with private insurance. However, patients with Medicare/Medicaid were significantly less likely to receive radiation therapy that was in turn associated with worse overall survival.

Q. How can these obstacles be reduced/overcome?

There are targeted access programs such as the Medicaid discount program and 340b for Medicare that provides financial assistance for chemotherapy. As these programs provide no financial assistance for radiation therapy, this study suggests that financial assistance programs for radiation therapy may be necessary to overcome financial barriers.

Q. What were the limitations of this study and what further studies are needed?

One of the limitations noted in the study was that the National Cancer Database looks only at overall survival and not at local control or cancer specific survival.3 However, given the aggressiveness of SCLC, overall survival is likely a good surrogate of other oncologic outcomes such as cancer specific survival. Further studies are certainly needed to determine whether targeted access and financial assistance programs can level the playing field and improve outcomes for uninsured patients and with Medicaid/Medicare.

Article Information:

Stephen G Chun has nothing
to disclose in relation to this article.

Review Process

This is an expert interview and, as such,
has not undergone the journal’s standard peer review


The named author meets the International
Committee of Medical Journal Editors (ICMJE) criteria
for authorship of this manuscript, takes responsibility
for the integrity of the work as a whole, and has given
final approval to the version to be published.


Stephen G Chun, The University
of Texas, MD Anderson Cancer Center, 1515 Holcombe
Blvd, Houston, TX 77030, US. E:


No funding was received in the publication of this article.


This article is published under the Creative
Commons Attribution Noncommercial License, which
permits any noncommercial use, distribution, adaptation,
and reproduction provided the original author(s) and
source are given appropriate credit. © The Authors 2018.


Medical writing assistance was
provided by Katrina Mountfort of Touch Medical Media, and
supported by Touch Medical Media.




  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. 2018;68:394–424.
  2. Alvarado-Luna G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now?-a review. Transl Lung Cancer Res. 2016;5:26–38.
  3. Pezzi TA, Schwartz DL, Mohamed ASR, et al. Barriers to combined-modality therapy for limited-stage small cell lung cancer. JAMA Oncol. 2018;4:e174504.
  4. Chun SG, Pezzi TA, Schwartz DL. Underutilization of combined-modality therapy in limited-stage small cell lung cancer-Reply. JAMA Oncol. 2018;4:1436–37.

Further Resources

Share this Article
Related Content In Lung Cancer
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72